• Privacy policy
  • T&C’s
  • About Us
    • FAQ
    • Meet the Team
  • Contact us
TLE ONLINE SHOP!
  • TLE
  • News
  • Politics
  • Business
  • Sport
  • Opinion
  • Elevenses
  • Entertainment
    • All Entertainment
    • Film
    • Lifestyle
      • Horoscopes
    • Lottery Results
      • Lotto
      • Thunderball
      • Set For Life
      • EuroMillions
  • Food
    • All Food
    • Recipes
  • Property
  • Travel
  • Tech/Auto
No Result
View All Result
The London Economic
SUPPORT THE LONDON ECONOMIC
NEWSLETTER
  • TLE
  • News
  • Politics
  • Business
  • Sport
  • Opinion
  • Elevenses
  • Entertainment
    • All Entertainment
    • Film
    • Lifestyle
      • Horoscopes
    • Lottery Results
      • Lotto
      • Thunderball
      • Set For Life
      • EuroMillions
  • Food
    • All Food
    • Recipes
  • Property
  • Travel
  • Tech/Auto
No Result
View All Result
The London Economic
No Result
View All Result
Home Prices and Markets

Sareum Holdings – Potential strategy in COVID-19

The pandemic presents Sareum with an unexpected opportunity to test its lead TYK2 inhibitor, SDC-1801, in COVID-19. Such a move would require external funding, but this could accelerate clinical development timelines and catalyse a substantial increase in value for the company. Meanwhile, the recent £1m fundraising allows Sareum to advance SDC-1801 towards trials for mainstream […]

Edward Marten by Edward Marten
2020-06-26 10:24
in Prices and Markets
FacebookTwitterLinkedinEmailWhatsapp

The pandemic presents Sareum with an unexpected opportunity to test its lead TYK2 inhibitor, SDC-1801, in COVID-19. Such a move would require external funding, but this could accelerate clinical development timelines and catalyse a substantial increase in value for the company. Meanwhile, the recent £1m fundraising allows Sareum to advance SDC-1801 towards trials for mainstream autoimmune conditions… Read more

Sareum intends to make grant applications to explore the activity of SDC-1801 in COVID-19, where the aim would be to reduce the immune system over-reaction that has been seen in the later phase of the infection. If such grant applications are awarded, SDC-1801 could join a group of drugs – including a number of JAK inhibitors – that have been fast-tracked into trials for COVID-19 As a dual TYK2/JAK1 inhibitor, SDC-1801 could be more effective and/or better tolerated than these similar compounds in treating COVID-19.

Meanwhile, Sareum has raised £1m via an equity issue that allows it to advance SDC-1801 into clinical trials for autoimmune disease, consistent with its original business plan.

While QuotedData’s model does not ascribe a value to the COVID-19 opportunity at present, the estimate of the TYK2 assets’ current value has been increased to $30-50m. After modest assumptions for research and development (R&D) spending, QuotedData has assigned a fair value for Sareum in the £25–45m range (0.76–1.38p/share), with the interest in SRA-737 representing upside to the investment case that may be realised in a deal involving the licensee Sierra Oncology.

Read more

NB: Marten & Co was paid to produce this note on Sareum Holdings Plc and it is for information purposes only. It is not intended to encourage the reader to deal in the
security or securities mentioned in this report. Please read the important information at the back of this note. QuotedData is a trading name of Marten & Co Limited which
is authorised and regulated by the FCA. Marten & Co is not permitted to provide investment advice to individual investors categorised as Retail Clients under the rules of
the Financial Conduct Authority.

RelatedPosts

Has Bitcoin bottomed out?

Five reasons why Bitcoin could be stuck in a temporary rut

Business Mogul Skeptical About Cryptocurrencies, Prefers NFTs

Nornickel’s GPF Rolls Out Instrument to Invest in Metals for Electric Car Industry

Subscribe to our Newsletter

View our  Privacy Policy and Terms & Conditions

Trending on TLE

  • All
  • trending
Abdollah

‘Rescue us’: Afghan teacher begs UK to help him escape Taliban

CHOMSKY: “If Corbyn had been elected, Britain would be pursuing a much more sane course”

What If We Got Rid Of Prisons?

More from TLE

Women are almost as likely to use social media for health advice as NHS, study finds

Creamy Lime and Condensed Milk Layered Fridge Tart

Corbyn is “playing” at this year’s Glastonbury

Where to watch the FA Cup in London this weekend

Study finds Brexit has ceased to be the “will of the people”

​Fat Tony’s​ pasta restaurant to pop-up at ​Bar Termini Centrale

TLE Meets…Funmbi

A quarter of small British firms see Brexit as a barrier to success

Tories walk away Scot-free from disaster year thanks to ‘biased press’

Great Barrier Reef ‘critical’ as climate change hits huge number of natural World Heritage Sites

About Us

TheLondonEconomic.com – Open, accessible and accountable news, sport, culture and lifestyle.

Read more

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.




No Result
View All Result
  • Home
  • News
  • Politics
  • Business
  • Sport
  • Entertainment
  • Lifestyle
  • Food
  • Travel
  • More…
    • Elevenses
    • Opinion
    • Property
    • Tech & Auto
  • About Us
    • Meet the Team
    • Privacy policy
  • Contact us

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.